| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
Nitidine chloride targets multiple cellular pathways. It inhibits STAT3 signaling cascade, DNA topoisomerase 1 and 2A, ERK, and c-Src/FAK associated signaling pathways. It also inhibits AKT signaling and downregulates NEDD4 expression. By inhibiting these pathways, nitidine chloride induces apoptosis, suppresses cell proliferation, and inhibits migration and invasion of cancer cells.
|
|---|---|
| ln Vitro |
In vitro, nitidine chloride inhibits the proliferation of various cancer cell lines in a time- and dose-dependent manner. It induces apoptosis and decreases STAT3 phosphorylation in HSC-3 and HSC-4 oral cancer cells. It inhibits the proliferation of SMMC-7721 cells. It suppresses cell activity, migration, and invasion, and induces apoptosis in lung carcinoma cells. It inhibits renal cancer cell metastasis by inhibiting the AKT signaling pathway and inhibits ovarian cancer cell migration and invasion by inhibiting MMP-2/9 production through the ERK signaling pathway.
|
| ln Vivo |
In vivo, nitidine chloride has demonstrated efficacy in mouse models. In a mouse model of hepatocellular carcinoma (HCC), nitidine chloride showed efficacy. In an HSC-3 oral cancer mouse xenograft model, nitidine chloride (10 mg/kg per day for 24 days) reduced tumor growth. In a breast cancer model (MDA-MB-231 cells in BALB/C nude mice), nitidine chloride at 5 mg/kg upregulated p53, p21, Bax, and cleaved caspase-9.
|
| Enzyme Assay |
In vitro assays for nitidine chloride typically measure its effects on cell proliferation, apoptosis, and signaling pathways. Cell viability is assessed by MTT or CCK-8 assays. Apoptosis is measured by flow cytometry using Annexin V staining or by caspase activity assays. Signaling pathway inhibition is assessed by Western blotting for phosphorylated and total proteins (e.g., STAT3, ERK, AKT). DNA topoisomerase activity can be measured using relaxation or decatenation assays.
|
| Cell Assay |
For cell-based assays, cancer cell lines are cultured in appropriate media. Cells are seeded in multi-well plates and treated with nitidine chloride at various concentrations (typically 1-50 μM) for 24-72 hours. Cell viability, apoptosis, and signaling pathway changes are assessed as described above. Migration and invasion are assessed using Transwell or wound-healing assays. All experiments include appropriate vehicle controls.
|
| Animal Protocol |
In vivo, nitidine chloride is typically administered intraperitoneally to mice. In xenograft models, tumor-bearing mice are treated with nitidine chloride at doses such as 5 mg/kg or 10 mg/kg daily. Tumor volume is measured over time. At the end of the study, tumors are excised for histology and biomarker analysis (e.g., p53, p21, Bax).
|
| ADME/Pharmacokinetics |
Nitidine chloride (MW 383.83, C₂₁H₁₈ClNO₄) is a benzophenanthridine alkaloid. It is a light yellow to yellow solid powder. The compound is typically stored as a powder at -20°C for long-term stability. Detailed pharmacokinetic parameters are not extensively reported. It is for research purposes.
|
| Toxicity/Toxicokinetics |
Nitidine chloride is for research use only and is not intended for human therapeutic applications. Toxicity data are limited. Standard safety pharmacology and toxicology studies would be required for therapeutic development.
|
| Additional Infomation |
Nitidine chloride is a research-grade natural alkaloid with potent anticancer and anti-inflammatory activities. Its primary applications include cancer research, immunology, and drug discovery. The compound is not an approved drug and has not entered clinical trials. It is commercially available from various chemical suppliers for research purposes only. Its mechanism involves multi-target inhibition of signaling pathways.
|
| Molecular Formula |
C21H18CLNO4
|
|---|---|
| Molecular Weight |
383.828
|
| Exact Mass |
383.092
|
| CAS # |
13063-04-2
|
| Related CAS # |
6872-57-7 (Nitidine cation); 13063-04-2 (chloride);
|
| PubChem CID |
25659
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.35g/cm3
|
| Boiling Point |
619ºC at 760 mmHg
|
| Melting Point |
281-282ºC
|
| Flash Point |
189.4ºC
|
| Vapour Pressure |
3.01E-15mmHg at 25°C
|
| Index of Refraction |
1.696
|
| LogP |
3.716
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
27
|
| Complexity |
516
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[Cl-].O1C([H])([H])OC2=C1C([H])=C1C(=C2[H])C([H])=C([H])C2C3=C([H])C(=C(C([H])=C3C([H])=[N+](C([H])([H])[H])C=21)OC([H])([H])[H])OC([H])([H])[H]
|
| InChi Key |
QLDAACVSUMUMOR-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C21H18NO4.ClH/c1-22-10-13-7-17(23-2)18(24-3)8-15(13)14-5-4-12-6-19-20(26-11-25-19)9-16(12)21(14)22;/h4-10H,11H2,1-3H3;1H/q+1;/p-1
|
| Chemical Name |
2,3-dimethoxy-12-methyl-[1,3]benzodioxolo[5,6-c]phenanthridin-12-ium;chloride
|
| Synonyms |
NSC146397NSC-146397NSC 146397Nitidine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~2 mg/mL (~5.21 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2 mg/mL (5.21 mM) in 15% Cremophor EL 85% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 1 mg/mL (2.61 mM) in 0.5% CMC-Na 0.5% Tween-80 (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6053 mL | 13.0266 mL | 26.0532 mL | |
| 5 mM | 0.5211 mL | 2.6053 mL | 5.2106 mL | |
| 10 mM | 0.2605 mL | 1.3027 mL | 2.6053 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
